Pharmacodynamics (PD) and Pharmacokinetics (PK) of E7389 (Eribulin, Halichondrin B Analog) During a Phase I Trial in Patients With Advanced Solid Tumors: A California Cancer Consortium Trial
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-015-2868-7
Full Text
Open PDFAbstract
Available in full text
Date
September 11, 2015
Authors
Publisher
Springer Science and Business Media LLC